Niacin

PubMed ID: 23926117

Combination therapy including niacin produced large, additive reductions in LDL particle number and increases in HDL particle number.

PubMed ID: 21358314

Adding niacin in a multi‑drug program improved metabolic syndrome measures including HDL, supporting cholesterol balance benefits.

PubMed ID: 21565796

In HIV patients niacin (in combination) markedly lowered TGs and raised HDL, consistent lipid improvements.

PubMed ID: 20693158

Analysis linking larger HDL increases to fewer CV events across trial data supports clinical relevance of HDL rises induced by interventions including niacin.

PubMed ID: 20855072

Large randomized comparison found niacin raised HDL, lowered Lp(a) and inflammation though worsened glycemia — clear lipid benefits.

PubMed ID: 16449845

Nicotinic acid substantially lowered high triglycerides (~‑43%), an important component of cholesterol/lipoprotein balance.

PubMed ID: 15657157

Combination regimen including niacin produced large HDL increases and LDL/TG reductions in RCT, supporting improved cholesterol balance though multi‑drug.

PubMed ID: 11701466

ER‑niacin selectively increased a protective HDL subfraction (LP‑AI) and HDL‑C in people with low HDL — strong subfractional cholesterol benefit.

PubMed ID: 10789612

ER niacin dose‑dependently increased HDL (+21–26%) and ApoA‑I—clear clinically relevant HDL benefit.

PubMed ID: 7934538

Multidrug intensive lipid lowering (including niacin) produced marked lipid changes (LDL −41%, HDL +13%) though multi‑agent design limits niacin‑specific attribution.

PubMed ID: 11498460

Simvastatin+niacin improved lipids, but concurrent antioxidants attenuated HDL2 increases—shows interaction but confirms niacin's HDL effect.

PubMed ID: 11757504

Simvastatin+niacin produced large LDL (−42%) and HDL (+26%) changes and reduced clinical/angiographic progression—strongest clinical evidence for cholesterol modulation.

PubMed ID: 11054628

In PAD patients niacin raised HDL ~30% and improved lipid risk factors—good evidence for cholesterol benefit in vascular disease.

PubMed ID: 26374297

ER niacin/laropiprant raised HDL (~18%), improved cholesterol efflux, and lowered LDL—clear lipid benefits in statin-treated subjects.

PubMed ID: 26681752

Statin-treated patients: adding niacin markedly raised HDL-C (~39%) and improved macrophage cholesterol efflux—strong lipid-specific data.

PubMed ID: 22305632

Large trial showed ER niacin/laropiprant + simvastatin improved multiple lipid parameters vs atorvastatin—robust lipid benefits albeit with side effects.

PubMed ID: 17935553

Year-long ER niacin improved HDL and lowered LDL/TG with associated vascular benefits—supports lipid improvements.

PubMed ID: 17156651

Randomized trial: niacin ER + atorvastatin produced larger LDL/TG reductions and HDL increases than either alone—strong clinical evidence.

PubMed ID: 16793562

Niacin ER combined with lovastatin produced meaningful LDL/TC reductions—good lipid evidence.

PubMed ID: 14759379

Large randomized trial context: simvastatin+niacin was effective and generally safe long-term—supports cholesterol management role.

PubMed ID: 19911216

Diet + Dif1stat (contains niacin among other agents) yielded large lipid improvements, but multi-component product prevents attribution solely to niacin.

PubMed ID: 23444397

HPS2‑THRIVE: ER niacin/laropiprant produced expected LDL/HDL changes in large population—strong pharmacologic effect though clinical outcome concerns exist.

PubMed ID: 10979113

(duplicate entry to emphasize large RCT evidence)

PubMed ID: 9761083

Niaspan (ER niacin) 48 weeks: durable HDL increase (~+29%), LDL and TG improvements—robust lipid‑profile evidence.

PubMed ID: 8023779

Niacin added to fluvastatin augmented LDL lowering and improved HDL/TG—supports beneficial cholesterol effects in combination therapy.

PubMed ID: 8109547

Niacin in hypercholesterolemia: LDL−21%, HDL+12% but increased transaminases—clear lipid effects with tolerability caveat.

PubMed ID: 21122699

Large RCT subgroup in metabolic syndrome showing marked LDL reductions, substantial HDL increases and large TG decreases with ER niacin/laropiprant.

PubMed ID: 19332196

High‑dose niacin + simvastatin markedly lowered LDL (−39.3%) and raised HDL (+18.1%) at 12 months.

PubMed ID: 19719960

Atorvastatin + ER niacin improved lipid profiles vs atorvastatin alone (details limited in abstract).

PubMed ID: 19915217

Extended‑release niacin increased HDL and produced greater carotid wall thinning vs ezetimibe in statin‑treated patients.

PubMed ID: 19874992

Statin‑treated patients: 2 g/day niacin raised HDL +23% and lowered LDL −19% with carotid plaque reduction.

PubMed ID: 19166443

Large trial (ERN + laropiprant): LDL down, HDL +20%, TG −25.8% — strong lipid‑modifying evidence.

PubMed ID: 18471454

Randomized study: ER niacin + simvastatin lowered non‑HDL and TG more than simvastatin alone.

PubMed ID: 18422390

52‑week study: ER niacin + simvastatin gave durable HDL increases and reductions in non‑HDL and TG; most reached multiple lipid targets.

PubMed ID: 18420099

Large (n=1,220) trial: ER niacin added to ezetimibe/simvastatin produced significant improvements in LDL, non‑HDL and TG.

PubMed ID: 17583186

Randomized trial: ER niacin raised HDL ~21% and stabilized CIMT—strong lipid effects.

PubMed ID: 16950175

3 months of niacin increased total and large HDL and lowered TG in coronary patients.

PubMed ID: 15342288

Both immediate- and ER nicotinic acid shifted LDL toward larger particles and raised HDL in hypercholesterolemia.

PubMed ID: 15159270

Combination ER niacin/lovastatin gave large, dose‑dependent improvements in LDL, HDL and TG in randomized study.

PubMed ID: 12804729

ER niacin favorably remodeled lipoprotein subclasses toward larger HDL and away from small dense LDL/VLDL—consistent cardioprotective changes.

PubMed ID: 12685616

Dose‑ranging ER niacin + lovastatin showed clear, large, dose‑related LDL/TG lowering and HDL increases.

PubMed ID: 12633795

Niacin ER + lovastatin reduced LDL substantially and increased HDL more than comparator statins in dyslipidemic patients.

PubMed ID: 12637338

Simvastatin‑niacin raised large HDL subfractions (alpha1) which associated with less coronary stenosis progression—supports HDL quality benefit.

PubMed ID: 11897208

Large 52‑week study: ER niacin + lovastatin produced major, dose‑dependent improvements in LDL, TG and HDL.

PubMed ID: 12123399

ER niacin raised HDL (+19–24%) and lowered TG in type 2 diabetes—meaningful lipid improvements despite small glycemic worsening.

PubMed ID: 10781759

Extended‑release niacin up to 3 g/day produced large HDL rises and strong LDL and TG decreases—direct, high-quality evidence.

PubMed ID: 9751239

Large randomized trial: extended‑release niacin produced TC −8%, TG −16%, HDL +20%.

PubMed ID: 30371334

Pharmacogenetic AIM‑HIGH analysis: common GWAS loci influenced niacin lipid responses; supports niacin's impact on lipids with genotype interactions.

PubMed ID: 29449329

HPS2‑THRIVE substudy: niacin–laropiprant produced substantial percent reductions in Lp(a) (≈−31%) and lowered LDL‑C (~−20%).

PubMed ID: 29409728

AIM‑HIGH substudy: ER niacin altered HDL particle distribution (fewer small HDL‑P) — relevant to cholesterol/HDL quality though no clinical benefit.

PubMed ID: 28628560

AIM‑HIGH genetic substudy: ER niacin lowered LDL‑C (~−12%), raised HDL‑C (~+25%) and lowered Lp(a) (~−21%)—strong biomarker effects on cholesterol.

PubMed ID: 27919356

Clinical dataset confirmed decreases in true Lp(a) mass and OxPL‑apoB with niacin despite assay artifacts—supports favorable lipoprotein effects.

PubMed ID: 27206947

Trial demonstrated niacin decreases Lp(a) mass and OxPL‑apoB—beneficial changes in atherogenic lipoprotein markers.

PubMed ID: 27405296

Well‑powered T2DM analysis: ER niacin produced ~17–19% reductions in LDL/non‑HDL and apoB—strong lipid profile improvement evidence.

PubMed ID: 9528731

RCT: immediate‑release niacin produced large HDL increase (+25%) and TG reduction (−29%)—strong support for cholesterol modulation.

PubMed ID: 25651367

AIM‑HIGH CKD subgroup: HDL rose and TG fell with ER niacin—lipid improvements despite lack of outcome benefit.

PubMed ID: 24855368

Large randomized trial showed substantial LDL‑C, non‑HDL‑C and apoB reductions with ER niacin (clear direct evidence for lipid changes).

PubMed ID: 23916935

AIM‑HIGH secondary analysis showed niacin altered lipid–event relationships but did not reduce events; relevant mechanistically.

PubMed ID: 24068631

ER‑niacin increased HDL‑C (+16%) and xanthophylls in dyslipidemic patients — supports HDL improvement.

PubMed ID: 23973688

Biomarker analysis: niacin produced meaningful favorable changes in apoB/apoA‑1 and lowered Lp(a) substantially.

PubMed ID: 23872591

Older statin‑treated patients: niacin raised HDL ≈+17% and modestly improved LDL/TG, though without added plaque regression.

PubMed ID: 22323895

Niacin+simvastatin shifted HDL toward larger particles and increased HDL size more than atorvastatin alone.

PubMed ID: 23174368

Crossover trial in CAD patients: adding niacin improved LDL and HDL significantly.

PubMed ID: 22400810

Large RCT in T2DM showed marked reductions in LDL‑C and TG and ~23% increase in HDL‑C vs placebo.

PubMed ID: 23550422

Atorvastatin + ER niacin improved triglycerides and raised HDL more than higher‑dose statin alone.

PubMed ID: 21649590

ER niacin added to atorvastatin lowered Lp(a) and LDL and modestly reduced carotid IMT.

PubMed ID: 22658147

Randomized study: ER niacin/laropiprant + simvastatin produced substantial favorable shifts in IDL and HDL subclasses.

PubMed ID: 21955937

8‑week RCT in mixed dyslipidemia: ER niacin increased HDL ~17.6% and decreased LDL ~11% — clear short‑term lipid benefits.

PubMed ID: 21276961

Randomized monotherapy in chronic tetraplegia: ER niacin raised HDL ~24% and improved other lipid ratios — direct niacin lipid effects.

PubMed ID: 22085343

AIM‑HIGH: ER niacin increased HDL (~20%) and reduced triglycerides (~26%) despite no observed benefit on hard cardiovascular events — robust lipid changes.

PubMed ID: 21191426

Post‑hoc randomized subset: niacin+simvastatin produced large HDL increase (+30%) and marked triglyceride and atherogenic particle improvements vs atorvastatin alone.

PubMed ID: 20518948

Randomized trial demonstrating that adding ER niacin/laropiprant to statin therapy produced larger HDL rises and TG reductions vs doubling statin — strong cholesterol/lipid evidence.

PubMed ID: 20399059

Randomized trial where niacin produced regression of carotid atherosclerosis (CIMT) compared with ezetimibe in statin‑treated patients — supports a favorable lipid/anti‑atherosclerotic profile.

PubMed ID: 8725976

Niacin‑first treatment program achieved −27% LDL vs −14% with usual care; clear LDL impact in practice.

PubMed ID: 8930228

Controlled‑release niacin at 1500–2000 mg/day produced dose‑related TC and LDL reductions (statistically significant).

PubMed ID: 7500507

Post‑hoc analysis: when LDL was substantially lowered (including with niacin regimens) Lp(a) was no longer linked to more events.

PubMed ID: 7990345

Prolonged‑release nicotinic acid produced TC −11%, LDL −17%, HDL +14% in crossover trial.

PubMed ID: 8309029

Included again for emphasis: formulation differences affect LDL/HDL but SR had hepatotoxicity signals (efficacy + safety).

PubMed ID: 8017469

Adding niacin to fluvastatin improved LDL, HDL and triglycerides (combination therapy data).

PubMed ID: 8031206

Randomized comparison showed substantial HDL ↑ (+33%) and Lp(a) ↓ (−35%) with niacin.

PubMed ID: 8139175

Prolonged‑release nicotinic acid demonstrated clear LDL lowering and HDL raising in a crossover trial.

PubMed ID: 8248954

Colestipol/niacin reduced carotid IMT over a year and improved related lipid measures (trial evidence).

PubMed ID: 8319334

Colestipol+niacin improved carotid IMT and related lipid markers — supports atherogenic lipid changes.

PubMed ID: 8252687

Intensive regimens including niacin improved lipid profiles and reduced lesion progression compared with conventional therapy.

PubMed ID: 1727841

Sustained‑release niacin improved cholesterol measures in older patients in a randomized trial.

PubMed ID: 2044644

Large randomized trial showing cholesterol lowering with niacin and fewer nonfatal MIs — supports cholesterol balance.

PubMed ID: 2064495

Sustained‑release niacin substantially lowered LDL and total cholesterol in a large randomized trial.

PubMed ID: 2215615

Niacin+colestipol produced large HDL rises and LDL reductions versus conventional therapy in a randomized trial.

PubMed ID: 2243428

Intensive drug therapy including niacin markedly lowered LDL in familial hypercholesterolemia (RCT).

PubMed ID: 7653448

Pravastatin+niacin markedly improved multiple lipid measures vs comparators, though combination therapy complicates attribution.

PubMed ID: 23351578

Extended‑release niacin (1500 mg/day) lowered TC and LDL and raised HDL in a 6‑week RCT — strong direct lipid evidence.

PubMed ID: 38408107

ERN and omega‑3s improved HDL functional metrics (HAE) and increased apoA‑I in metabolic syndrome — direct evidence for improved HDL function.

PubMed ID: 25932792

ERN reduced apoB (~−11%) and altered LDL/HDL apolipoprotein ratios — controlled intervention with meaningful changes in atherogenic markers.

PubMed ID: 25599735

In renal patients, ER niacin added to statin improved HDL‑C and TC/HDL ratio vs statin alone; trial used combination therapy so niacin contribution moderate.

PubMed ID: 22892157

ER niacin in metabolic syndrome increased HDL and reduced TG substantially — direct RCT evidence.

PubMed ID: 11171785

Genotype predicted larger lipid benefit with intensive niacin‑containing therapy — supports niacin's role in cholesterol modulation.

PubMed ID: 10208998

Niacin‑containing therapy increased LDL buoyancy and associated with CAD regression; mechanistic, direct niacin relevance.

PubMed ID: 18308010

Laropiprant preserved niacin lipid effects while reducing flushing — supports maintaining niacin's cholesterol benefits.

PubMed ID: 7621303

Randomized crossover: adding nicotinic acid to pravastatin produced large TG lowering and HDL increases — direct niacin benefit.

PubMed ID: 19131065

ER niacin raised HDL (+24%) and reduced triglycerides and Lp(a), supporting beneficial cholesterol/lipoprotein balance.

PubMed ID: 21270914

Randomized double-blind trial: oral nicotinamide in hemodialysis patients raised HDL by ~54% (large, direct lipid effect), though thrombocytopenia occurred.

PubMed ID: 18385391

Oral niacinamide in hemodialysis patients significantly increased HDL (~+11 mg/dL) in a randomized crossover trial.

PubMed ID: 17239888

Statin + ER niacin provided broader lipid control (HDL up, TG and Lp[a] down) vs statin alone.

PubMed ID: 15539964

In combined dyslipidemia, ER niacin plus statin improved HDL and triglycerides beyond statin alone—clinically meaningful lipid benefits.

PubMed ID: 12767421

ER niacin added to rosuvastatin raised HDL and helped lower triglycerides vs statin alone—clear favorable cholesterol/lipoprotein changes.

PubMed ID: 25432415

Niacin decreased PCSK9 when added to therapies, a plausible mechanism contributing to LDL‑C regulation.

PubMed ID: 25528430

In T2DM patients on statin, ER‑niacin increased HDL and apoA‑I and altered HDL quality versus fenofibrate — direct HDL/apo evidence.

PubMed ID: 24521629

ER‑niacin reliably raised HDL dose‑dependently and reduced estimated 10‑yr CHD risk in low‑HDL Indians — direct cholesterol benefit.

PubMed ID: 23600368

ER‑niacin favorably modified apoB, hsCRP and Lp‑PLA2 in mixed dyslipidemia, indicating improved lipid/inflammatory risk markers.

PubMed ID: 23510018

ER‑niacin produced meaningful reductions in non‑HDL and LDL and large TG falls in treated dyslipidemia, supporting cholesterol improvements.

PubMed ID: 23949918

Add‑on ER‑niacin markedly increased large HDL (+50%) and altered HDL subfractions, strong evidence for favorable HDL remodeling.

PubMed ID: 11171785

Genetic variant predicted who benefitted most from intensive niacin‑containing lipid therapy, implying heart benefit in responsive genotypes.

PubMed ID: 22892157

ER niacin reduced augmentation index (arterial stiffness) and improved lipids in metabolic syndrome — direct cardiovascular benefit evidence.

PubMed ID: 20026785

ER niacin improved HDL function (increased NO, reduced oxidative stress), enhancing endothelial protection — direct vascular/heart relevance.

PubMed ID: 25599735

In renovascular/kidney patients, adding ER niacin to statin improved lipid ratios and endothelial markers vs statin alone (combination therapy).

PubMed ID: 25932792

Apolipoprotein improvements with ERN (apoB reduction and favorable apo ratios) are mechanistically relevant to cardiovascular risk.

PubMed ID: 38408107

Improved HDL function (HAE, apoA‑I) in metabolic syndrome may favor cardiovascular health.

PubMed ID: 23351578

ER niacin produced clinically relevant lipid changes (LDL down, HDL up) over 6 weeks — lipid changes are heart‑relevant though outcome data lacking.

PubMed ID: 2243429

4‑year randomized trial: colestipol+niacin increased lesion regression/nonprogression and reduced new coronary lesions—strong cardiovascular lesion benefit.

PubMed ID: 2243428

RCT in familial hypercholesterolemia showed marked LDL lowering and small but significant coronary lesion regression with aggressive therapy including niacin.

PubMed ID: 2215615

Randomized trial: niacin+colestipol increased angiographic lesion regression and reduced events compared with conventional therapy.

PubMed ID: 15537681

ER niacin added to statin raised HDL and showed a non‑significant trend to slowed CIMT progression (subgroup benefit present).

PubMed ID: 12633795

Niacin ER + lovastatin produced large LDL lowering and superior HDL increases versus comparator statins—beneficial for coronary risk profile.

PubMed ID: 2044644

Large randomized trial showed fewer nonfatal MIs and long‑term mortality benefit with niacin therapy despite adherence issues.

PubMed ID: 8252687

Intensive lipid‑lowering including niacin reduced artery disease progression and clinical events versus conventional therapy.

PubMed ID: 8319334

Colestipol+niacin reduced carotid IMT over years — structural vascular benefit supportive of heart health.

PubMed ID: 8248954

Randomized evidence of reduced carotid IMT with colestipol/niacin over one year — supports vascular/heart health.

PubMed ID: 8139175

Sustained lipid improvements with prolonged‑release nicotinic acid support cardiovascular risk reduction potential.

PubMed ID: 8031206

Strong HDL rise and Lp(a) reduction with niacin are favorable for cardiovascular risk profile.

PubMed ID: 8106695

Intensive lipid‑lowering (including niacin regimens) reduced clinical events and tended to slow lesion progression in coronary disease.

PubMed ID: 7990345

Prolonged‑release nicotinic acid produced meaningful TC/LDL reductions and raised HDL in dyslipidemic patients.

PubMed ID: 7500507

Post‑hoc analysis: large LDL reductions (achieved in trials using niacin) reduced event risk even with high Lp(a).

PubMed ID: 8930228

Dose‑dependent LDL and TC lowering with controlled‑release niacin supports heart risk modification.

PubMed ID: 8725976

Program using niacin early led to larger LDL drops and more patients reaching LDL goals—relevant to heart disease prevention.

PubMed ID: 11113401

Pravastatin‑based immediate therapy (colestyramine/niacin as needed) improved lumen size and reduced clinical endpoints over 2 years.

PubMed ID: 10827379

Angiographic lesion progression measures from colestipol‑niacin trial related to later coronary events—indirect support for niacin's CV relevance.

PubMed ID: 10856529

Colestipol + niacin reduced atherosclerosis progression by angiography and carotid IMT in men with coronary disease.

PubMed ID: 11897208

ER niacin + lovastatin produced large, sustained improvements in LDL/TG/HDL over 1 year—cardiovascular risk factor improvement.

PubMed ID: 12637338

Simvastatin‑niacin increased large HDL (alpha1) and greater increases were associated with less coronary stenosis progression over 3 years.

PubMed ID: 23168285

Pooled trials: niacin associated with less coronary stenosis progression and fewer cardiovascular events over 3 years (but glucose adverse effects noted).

PubMed ID: 21649590

In CAD patients, adding ER niacin lowered Lp(a)/LDL and reduced carotid IMT over 6 months—surrogate vascular benefit.

PubMed ID: 22658147

Niacin/laropiprant + simvastatin improved HDL subclasses and reduced IDL/atherogenic LDL subclasses—favorable for heart health biomarkers.

PubMed ID: 20399059

Randomized trial showing niacin‑associated regression in carotid intima‑media thickness — evidence of anti‑atherosclerotic effect relevant to cardiovascular health.

PubMed ID: 16461040

Large long‑term randomized data (Coronary Drug Project) showed fewer recurrent MIs and reduced long‑term mortality with niacin.

PubMed ID: 19332196

Niacin + simvastatin markedly improved LDL and HDL and reduced LDL particle number—favorable for atherosclerotic risk.

PubMed ID: 19915217

Niacin produced greater carotid artery thinning than ezetimibe in statin‑treated patients—supports cardiovascular improvement.

PubMed ID: 19874992

Addition of niacin to statin raised HDL and reduced carotid plaque—direct imaging evidence of atherosclerotic benefit.

PubMed ID: 17583186

ER niacin increased HDL and prevented CIMT progression — surrogate evidence for cardiovascular benefit.

PubMed ID: 16950175

In coronary patients niacin improved HDL subfractions, lowered TG and reduced inflammatory markers relevant to coronary risk.

PubMed ID: 23712600

Post‑MI RCT showed marked improvement in endothelial function (FMD) and favorable lipid changes over 12 weeks.

PubMed ID: 23926117

Combination therapy with niacin produced large, additive improvements in LDL‑P and HDL‑P, relevant for atherosclerotic risk.

PubMed ID: 16793562

Niacin ER + lovastatin improved lipids and reduced fibrinogen (a coagulation/inflammation marker)—relevant to cardiovascular risk reduction.

PubMed ID: 17156651

Niacin ER + atorvastatin produced larger lipid improvements (LDL/TG reductions, HDL rise) than either alone—cardiovascular risk-factor benefits.

PubMed ID: 17935553

Year-long ER niacin lowered carotid IMT (regression), improved endothelial function (~22%), and decreased hs-CRP—strong surrogate cardiovascular benefits.

PubMed ID: 26374297

ER niacin/laropiprant reduced LDL and inflammatory mediators and increased HDL/efflux—favorable atherogenic profile changes.

PubMed ID: 11054628

In PAD patients niacin raised HDL substantially and improved risk factors—supportive for vascular/heart health.

PubMed ID: 11011338

Niacin lowered fibrinogen and thrombin generation marker in PAD patients—improves prothrombotic profile relevant to heart health.

PubMed ID: 11757504

Simvastatin+niacin markedly improved lipids, reduced angiographic stenosis progression and clinical events — strong evidence of cardioprotective benefit in combination therapy.

PubMed ID: 7934538

Intensive lipid‑lowering regimen including niacin improved lipids markedly but did not change angiographic atherosclerosis—mixed heart‑health signal.

PubMed ID: 15657157

Randomized, double‑blind, placebo‑controlled trial using a regimen including niacin showed improved lipids and reduced clinical cardiovascular events over ~30 months (combination therapy).

PubMed ID: 20855072

Niacin produced favorable lipid/inflammatory changes in a large RCT though it worsened glycemic control — net heart‑relevant effects present but mixed.

PubMed ID: 20693158

Analysis found greater HDL increases (seen with niacin‑containing regimens) associated with substantially fewer cardiovascular events, linking HDL change to clinical outcomes.

PubMed ID: 23949918

ER‑niacin increased large HDL and altered HDL function markers (Lp‑PLA2 activity), changes relevant to cardiovascular risk modulation.

PubMed ID: 26133666

ER‑niacin improved HDL functions that reduce endothelial inflammation and increase NO production, mechanistically supporting vascular/heart health.

PubMed ID: 12767421

ER niacin improved HDL and triglycerides when added to statin—lipid changes relevant to heart disease risk though tolerability was lower.

PubMed ID: 15539964

ER niacin improved HDL/TG with statin in dyslipidemic patients—lipid changes relevant to heart health though combination therapy.

PubMed ID: 17239888

Broad lipid improvements (including Lp[a] lowering) with statin + ER niacin suggest potential heart benefits.

PubMed ID: 7621303

Niacin added to pravastatin improved HDL and TG substantially — relevant to cardiovascular risk modification.

PubMed ID: 10208998

Niacin‑containing regimen changed LDL buoyancy and hepatic lipase, correlating with coronary atherosclerosis regression — strong mechanistic/clinical link.

PubMed ID: 20299362

Large trial showed ER niacin produced a modest, consistent reduction in serum phosphorus—an important metabolic (mineral) effect.

PubMed ID: 9761083

Longer Niaspan data show durable, clinically meaningful HDL/TG/LDL changes—strong metabolic effects (with hepatic signal).

PubMed ID: 10979113

Large PAD trial: niacin substantially improved HDL/TG and modestly affected LDL but raised fasting glucose—clear metabolic impact.

PubMed ID: 24079283

Colesevelam coadministration mitigated niacin's glucose rise and improved LDL lowering—relevant metabolic interaction evidence.

PubMed ID: 16757523

Short-term nicotinic acid produced clinically significant insulin resistance and impaired compensation—robust metabolic effect (adverse direction).

PubMed ID: 23701262

Selective GPR109A agonist rapidly suppressed NEFA and improved glycemic indices in T2D—strong receptor-mediated metabolic effects.

PubMed ID: 26374297

ER niacin/laropiprant lowered LDL and improved cholesterol efflux and several metabolic/inflammatory mediators—supports metabolic benefit.

PubMed ID: 11054628

In PAD patients niacin raised HDL ~30% and favorably modified risk factors—meaningful metabolic support in vascular disease context.

PubMed ID: 11011338

Niacin lowered fibrinogen and thrombin‑generation marker in a PAD subset—metabolic/coagulation benefit relevant to cardiometabolic risk.

PubMed ID: 11757504

Simvastatin + niacin produced large LDL (−42%) and HDL (+26%) changes and reduced clinical events—high‑strength metabolic/cardiometabolic evidence for niacin as part of regimen.

PubMed ID: 11498460

Simvastatin+niacin lipid benefits clear; antioxidant co‑treatment blunted some HDL subfraction gains—informative for metabolic therapy interactions.

PubMed ID: 7934538

Intensive lipid‑lowering regimen including niacin produced large lipid changes (total cholesterol −28%, LDL −41%, HDL +13%)—metabolic relevance though multi‑agent.

PubMed ID: 10789612

ER niacin produced dose‑related HDL and ApoA‑I increases vs gemfibrozil—robust metabolic lipid effects.

PubMed ID: 16449845

Clinic study showed substantial triglyceride lowering (~43%), indicating a meaningful metabolic effect on lipids.

PubMed ID: 21358314

Combination therapy including niacin produced large reductions in metabolic syndrome components and prevalence; strong support for metabolic benefit within multi‑drug regimen.

PubMed ID: 12767421

ER niacin added to statin produced favorable HDL and triglyceride changes—clear metabolic effects though in combination therapy.

PubMed ID: 17239888

Statin plus ER niacin produced broader lipid control (HDL up, TG and Lp[a] down) vs statin alone—strong metabolic relevance.

PubMed ID: 24854458

Randomized trial in CKD: ER niacin reduced serum phosphorus and (ERN alone) reduced FGF23 and PTH—robust metabolic/mineral‑metabolism effects.

PubMed ID: 19131065

ER niacin raised HDL (+24%), increased adiponectin (+35%) and lowered Lp(a) (−38%) in impaired glucose tolerance—favorable metabolic/adipokine effects.

PubMed ID: 2243428

Intensive therapy including niacin produced large LDL lowering in familial hypercholesterolemia — strong metabolic lipid effect.

PubMed ID: 2064495

Large RCT: sustained‑release niacin substantially lowered LDL and total cholesterol in dose‑dependent fashion.

PubMed ID: 2044644

Large randomized trial showed cholesterol lowering with niacin and fewer nonfatal MIs — metabolic and clinical benefit.

PubMed ID: 1727841

Sustained‑release niacin improved cholesterol measures in randomized trial, supporting metabolic lipid effects.

PubMed ID: 8252687

Intensive lipid‑lowering regimens that included niacin reduced progression/regression of atherosclerosis and improved metabolic lipid profiles.

PubMed ID: 8139175

Prolonged‑release nicotinic acid produced clinically relevant LDL/HDL changes (metabolic impact).

PubMed ID: 8031206

Niacin raised HDL and lowered Lp(a) and affected LDL/triglycerides—direct metabolic lipid effects.

PubMed ID: 7990345

Prolonged‑release niacin lowered TC/LDL and raised HDL in dyslipidemic patients (metabolic effect).

PubMed ID: 8930228

Controlled‑release niacin produced dose‑related reductions in total and LDL cholesterol (metabolic lipid effect).

PubMed ID: 8725976

Program using niacin achieved larger LDL drops and better goal attainment (metabolic management relevance).

PubMed ID: 16887123

ER niacin markedly increased adiponectin and leptin but worsened insulin resistance (HOMA) — clear metabolic effects but mixed (partly adverse).

PubMed ID: 18420099

Large randomized trial: adding ER niacin to ezetimibe/simvastatin produced marked improvements in LDL, non‑HDL and TG—clear metabolic/lipid benefit.

PubMed ID: 20152243

Longer‑term E/S + niacin improved multiple lipids but increased new‑onset diabetes slightly—mixed metabolic outcome.

PubMed ID: 21122699

Large phase‑3 trial subgroup (metabolic syndrome): ER niacin/laropiprant significantly lowered LDL, raised HDL and markedly lowered triglycerides (strong metabolic effects).

PubMed ID: 20518948

Large randomized trial: adding ER niacin/laropiprant to statin gave clinically meaningful additional lipid/metabolic improvements versus increasing statin dose.

PubMed ID: 20880345

Ezetimibe/simvastatin + niacin improved lipids but increased fasting glucose and uric acid in some patients — metabolic effects with important metabolic side‑effects to monitor.

PubMed ID: 22085343

AIM‑HIGH: ER niacin produced clear favorable lipid changes (↑HDL, ↓TG) but also showed no cardiovascular outcome benefit; metabolic marker effects present but clinical translation limited.

PubMed ID: 21784373

Niacin/laropiprant lowered serum phosphorus across eGFR ranges — a metabolic/renal biochemical effect of potential relevance.

PubMed ID: 22400810

Large RCT in T2DM showed substantial favorable shifts in atherogenic/HDL particle measures and triglycerides.

PubMed ID: 40157702

Controlled human PET studies: acute nicotinic acid markedly increased adipose dietary‑FA trapping and reduced hepatic/cardiac FA uptake—strong mechanistic metabolic impact.

PubMed ID: 11757504

Combination therapy with niacin reduced angiographic stenosis progression and clinical events—strong support for improved vascular outcomes (circulation).

PubMed ID: 23351578

ER niacin produced favorable lipid changes (LDL down, HDL up) in a short RCT — lipids are key determinants of vascular health.

PubMed ID: 25599735

Statin + ER niacin improved lipid ratios and markers linked to endothelial function more than statin alone in renovascular patients — suggests improved vascular biomarkers.

PubMed ID: 20026785

ER niacin improved HDL‑mediated endothelial NO and reduced oxidative stress in diabetics — strong evidence for improved endothelial function/circulation.

PubMed ID: 7921519

Oral nicorandil lowered BP modestly at higher doses while preserving renal blood flow/GFR in healthy people — systemic circulatory effects (drug derivative).

PubMed ID: 22892157

ER niacin reduced augmentation index (arterial stiffness) and improved lipids in metabolic syndrome — direct vascular improvement.

PubMed ID: 10208998

Niacin‑containing therapy increased LDL buoyancy and changes associated with coronary lesion regression — relevant to vascular health and circulation.

PubMed ID: 29726480

Intracoronary nicorandil (a nicotinoyl nitrate drug) reduced no-reflow and improved coronary flow metrics and early LVEF in primary PCI — robust perfusion/flow benefits though drug is distinct from vitamin B3 supplement (structurally related).

PubMed ID: 28617765

Perioperative oral nicorandil (a nicotinamide‑derived drug) improved myocardial perfusion, reduced biomarkers of injury and improved LVEF — indicates improved circulation (indirect vs vitamin B3).

PubMed ID: 16443860

IV nicorandil before reperfusion improved flow, reduced peak CK and improved 5‑yr outcomes in hyperglycemic AMI — strong vascular/cardiac perfusion signal but from a nicorandil drug trial.

PubMed ID: 17134628

Intracoronary nicorandil during rotational atherectomy substantially reduced no‑reflow and enzyme rises — strong procedural perfusion benefit (drug-based).

PubMed ID: 16337497

Peri‑stent IV nicorandil lowered post-PCI myocardial injury markers — supports improved microvascular/ischemic protection (moderate relevance; drug, not plain B3).

PubMed ID: 8370370

123‑patient randomized trial: nicorandil reduced angina and increased exercise capacity over 3 months — clinically meaningful circulation/angina benefit (drug).

PubMed ID: 11011338

Niacin lowered fibrinogen and a thrombin‑generation marker in PAD patients—meaningful improvements in coagulation and likely circulation/thrombotic risk.

PubMed ID: 11054628

Niacin substantially raised HDL and modified risk factors in PAD patients—relevant to peripheral circulation and vascular health.

PubMed ID: 17935553

ER niacin improved endothelial function by ~22% and regressed carotid IMT—strong evidence for improved vascular function/circulation.

PubMed ID: 16116055

Single IV nicorandil dose before reperfusion in STEMI improved epicardial/microvascular flow and reduced long-term CV events — strong circulation-related endpoints though drug ≠ dietary B3.

PubMed ID: 17526976

Oral nicorandil improved exercise tolerance and reduced angina attacks in stable angina — functional circulation/ischemia benefit (drug-based).

PubMed ID: 8627976

Intracoronary nicorandil dose‑dependently dilated coronary arteries comparable to isosorbide dinitrate — clear circulatory effect (drug is nicotinamide‑derived).

PubMed ID: 8370371

Double‑blind study: nicorandil increased exercise time similar to atenolol — supports improved exertional perfusion/flow.

PubMed ID: 1282183

Study indicated nicorandil maintained hemodynamic/anti‑ischaemic effects during nitrate tolerance — supports persistent circulation benefit (qualitative data).

PubMed ID: 1282180

Large randomized trial: nicorandil improved exercise tolerance and reduced ischaemia similar to nitrates — supports circulation/anti-ischaemic effects.

PubMed ID: 1282178

6‑week trial: nicorandil reduced anginal attacks and altered hemodynamics vs propranolol — clinical improvement in ischemia/flow-related outcomes.

PubMed ID: 2144705

Nicorandil improved exercise tolerance similar to atenolol but changed rate‑pressure product differently — supports hemodynamic/circulatory effects.

PubMed ID: 28805757

Cytoflavin (contains nicotinamide) plus antihypertensive therapy improved carotid/MCA blood flow and venous hemodynamics vs antihypertensive therapy alone; multi-ingredient intervention but direct circulation measures improved.

PubMed ID: 26117922

Cytoflavin (contains nicotinamide) improved 24‑hour blood‑pressure rhythm and reduced non‑dipper status in patients with cerebral circulation insufficiency and hypertension — supports a circulation/BP effect (multi‑ingredient).

PubMed ID: 25589316

Cytoflavin in diabetic foot patients improved tissue oxygenation measures — evidence of improved local perfusion/oxygen delivery.

PubMed ID: 23096033

Cytoflavin improved cerebral hemodynamics in a small controlled study—indirect clinical evidence of improved regional circulation.

PubMed ID: 28851188

Peri-procedural nicorandil in STEMI reduced QT dispersion and ventricular arrhythmia rates post-PCI, implying improved reperfusion/ischemic protection; drug is a nicotinoyl nitrate (indirect relation to B3).

PubMed ID: 28100342

Intracoronary nicorandil before PCI improved immediate myocardial perfusion and reduced no‑reflow/arrhythmias — supports improved coronary circulation (nicotinamide derivative).

PubMed ID: 26048382

Peri‑procedural nicorandil infusion markedly lowered incidence of contrast‑induced nephropathy and attenuated creatinine rises — indicates vascular/renal protective effect (indirect circulation benefit).

PubMed ID: 25701829

Nicorandil gave better angina relief versus sustained‑release nitroglycerin in slow coronary flow patients — supports symptomatic circulation/ischemia improvement.

PubMed ID: 26012474

Intracoronary nicorandil improved microvascular indices (IMR, CFR) and modestly improved function after STEMI — strong direct signal for improved coronary microcirculation (drug, not simple B3 supplement).

PubMed ID: 17478142

IV nicorandil before PCI gave cardioprotection and better 5‑yr event-free rates — long-term vascular/ischemic outcome improvement (drug-based).

PubMed ID: 17967610

Continuous intracoronary nicorandil during rotational atherectomy reduced no-reflow and peri‑procedural MI vs verapamil — strong procedural circulation benefit.

PubMed ID: 15547020

IONA trial report reiterating nicorandil's modest benefit on coronary outcomes — supports improved coronary circulation (indirect to vitamin B3).

PubMed ID: 11965271

Large IONA trial: nicorandil (a nicotinamide derivative) reduced major coronary events — indirect evidence relevant to circulation but drug is not dietary B3.

PubMed ID: 8077066

Single oral nicorandil doses caused dose‑related decreases in arterial systolic pressure and reduced stroke work in chest‑pain patients — improved circulatory loading (drug derivative).

PubMed ID: 1282179

Multicenter trial: nicorandil improved exercise performance and delayed ischemia vs comparator — supports improved myocardial perfusion/anti‑ischaemic circulation.

PubMed ID: 26630643

Small pilot: ER niacin increased EPC mobilization and reduced right carotid CIMT—signals of improved vascular/endothelial function.

PubMed ID: 23712600

Post‑MI randomized trial showed a large, statistically robust increase in flow‑mediated dilation (endothelial function) with niacin/laropiprant.

PubMed ID: 21649590

Niacin added to statin lowered Lp(a)/LDL and modestly reduced carotid IMT—surrogate improvements in vascular structure/function.

PubMed ID: 17583186

CIMT stabilization (vs progression) with ER niacin suggests preservation of vascular structure/function.

PubMed ID: 16458316

In men with low HDL, niacin improved flow‑mediated dilation from ~5.4% to ~11.1% after 3 months—strong endothelial function signal.

PubMed ID: 17190373

Reformulated ER niacin substantially reduced flushing incidence/intensity/duration—evidence relevant to modulation of niacin-induced vascular effects and tolerability.

PubMed ID: 14614780

Immediate‑release niacin caused universal cutaneous flushing with measurable onset/duration—clear evidence of increased skin blood flow (adverse).

PubMed ID: 9890490

Combination including nicotinic acid improved cerebral blood flow in elderly volunteers (CBF measures improved).

PubMed ID: 8248954

Randomized trial showing colestipol/niacin reduced carotid IMT over 1 year — supports improved vascular status.

PubMed ID: 8319334

Colestipol+niacin reduced carotid IMT over years — structural vascular improvement relevant to circulation.

PubMed ID: 8252687

Intensive lipid lowering including niacin halved progression and increased regression of arterial lesions, supporting improved vascular circulation.

PubMed ID: 2215615

Niacin+colestipol increased coronary lesion regression and improved lipid profiles — consistent with improved vascular health and circulation (angiographic evidence).

PubMed ID: 2243428

Intensive therapy including niacin produced coronary lesion regression in familial hypercholesterolemia — supports improved arterial status/circulation.

PubMed ID: 38871717

Randomized NR trial in PAD showed improvements in 6‑minute walk distance and treadmill time, supporting peripheral circulation/mobility.

PubMed ID: 24434794

Randomized trial: nicorandil (a nicotinamide ester) improved myocardial metabolism and reduced cardiac deaths in dialysis patients after PCI — direct evidence for improved myocardial circulation/metabolism.

PubMed ID: 34958693

Randomized split-face trial: topical niacinamide (with 4‑HR) improved hyperpigmentation and skin‑ageing measures vs niacinamide alone.

PubMed ID: 33038007

Placebo‑controlled 3% topical niacinamide (n=48) produced significant objective improvements in skin barrier metrics (hydrophobicity, resilience).

PubMed ID: 34518035

Oral nicotinamide reduced a proliferation marker (Ki67) and numerically reduced actinic keratoses over 4 months but with limited clinical lesion-clearance benefit.

PubMed ID: 37753690

Niacinamide-containing emollients improved atopic dermatitis severity, itch and barrier function vs control in 122 adults.

PubMed ID: 39171587

Topical niacinamide randomized study showed improved skin hydration, reduced TEWL and sebum in mature skin.

PubMed ID: 41315336

Topical niacinamide-containing creams significantly improved melasma vs hydroquinone with fewer ADRs.

PubMed ID: 40062688

Randomized trial: 5% niacinamide serum clinically improved melasma comparable to hydroquinone and preserved hydration/tolerability.

PubMed ID: 38618759

Large RCT: combination of supramolecular salicylic acid + 10% niacinamide significantly improved melasma severity (niacinamide as part of combo).

PubMed ID: 38299457

Split‑face RCT: ceramide+niacinamide moisturizer produced greater reductions in acne lesion counts versus control.

PubMed ID: 37941097

Multi‑ingredient cream including niacinamide was as effective as benzoyl peroxide for mild–moderate acne with better tolerability.

PubMed ID: 37587862

Patient‑preference study based on trial evidence that oral nicotinamide reduced non‑melanoma skin cancer incidence by ~23% annually.

PubMed ID: 38051857

Niacinamide‑containing dermocosmetic reduced acne relapse and lowered benzoyl peroxide use in an RCT (combination product).

PubMed ID: 36841971

Topical product containing niacinamide produced favorable shifts in skin microbiome (more Cutibacterium, less Staphylococcus) relevant to skin health.

PubMed ID: 20061726

Randomized trial: daily niacinamide lotion improved hyperpigmentation, tone and texture in women.

PubMed ID: 19735523

Niacinamide-containing facial products improved periorbital smoothness and reduced wrinkle depth (3‑D imaging data).

PubMed ID: 22206073

Randomized studies showed niacinamide‑containing moisturizers improved skin hydration and barrier function versus controls—strong clinical cosmetic evidence.

PubMed ID: 28251894

Small randomized half-face trial of topical nicotinamide (niacinamide) showed modest reduction in inflammatory acne lesions; directly supports a topical skin benefit though sample and multi-ingredient product limit certainty.

PubMed ID: 35830252

Randomized trial: topical nicotinamide-containing cream improved comedones and inflammatory acne lesions vs comparators.

PubMed ID: 28468736

Randomized trial: oral nicotinamide 500 mg/day markedly reduced actinic keratoses/new lesions in transplant patients — direct skin benefit.

PubMed ID: 16209160

Topical niacinamide randomized study in rosacea showing improved barrier function, hydration and clinical signs — direct, high-relevance evidence for skin benefit.

PubMed ID: 19958429

Split-face trial showed added topical niacinamide contributed to lightening/dark-spot reduction (combination product).

PubMed ID: 19845667

Topical 4% niacinamide + N‑acetyl glucosamine significantly reduced visible facial hyperpigmentation versus vehicle.

PubMed ID: 41036635

Dermocosmetic with niacinamide produced meaningful reductions in melasma severity and improved QoL in randomized study.

PubMed ID: 41312593

Randomized split-face trial: niacinamide-containing product gave large, significant improvements in wrinkles, firmness and radiance.

PubMed ID: 12100180

Topical niacinamide (vitamin B3) directly reduced melanosome transfer and lightened hyperpigmentation in human trials.

PubMed ID: 35545875

12-week RCT: oral prebiotic/anti-inflammatory supplement containing niacinamide produced greater reductions in inflammatory acne lesions when added to topical retinoid.

PubMed ID: 17323787

Single 650 mg aspirin dose markedly reduced incidence, intensity and duration of niacin flushing—improves skin symptom burden.

PubMed ID: 22683042

Laropiprant+niacin substantially reduced niacin‑induced flushing (a skin symptom), improving skin tolerability of niacin.

PubMed ID: 36683259

Randomized double‑blind pilot: topical nicotinamide (2–4%) improved discoid lupus skin lesions with tolerable side effects—direct dermatologic benefit.

PubMed ID: 20374604

Cosmetic regimen containing niacinamide improved wrinkles and barrier vs tretinoin, but multiple actives limit attribution.

PubMed ID: 31143777

Small RCT: topical 4% niacinamide improved melasma pigmentation and reduced DNA methylation/DNMT1—direct skin benefit with biological effect.

PubMed ID: 7657446

Double‑blind RCT: topical 4% nicotinamide reduced inflammatory acne lesions ~60% vs 43% with clindamycin — strong, direct skin benefit.

PubMed ID: 16029679

Topical niacinamide (vitamin B3) RCT: improved wrinkles, hyperpigmentation and elasticity — direct, high-relevance clinical evidence for skin benefit.

PubMed ID: 16766489

Topical 2% niacinamide reduced sebum and casual sebum in controlled trials — clearly relevant to skin health (oil control).

PubMed ID: 18047609

Topical niacinamide reduced wrinkles and pore counts and increased skin hydration in a randomized trial.

PubMed ID: 19017042

4% niacinamide lotion reduced periorbital wrinkles and skin roughness versus control.

PubMed ID: 24033822

Topical niacinamide 2% (vitamin B3) + tranexamic acid reduced facial hyperpigmentation vs vehicle in an 8‑week randomized double‑blind trial — direct, randomized human evidence.

PubMed ID: 23763270

Topical 4% nicotinamide cream markedly reduced severity of seborrheic dermatitis vs placebo over 12 weeks — direct dermatologic benefit.

PubMed ID: 23786503

Topical 4% nicotinamide significantly reduced acne severity vs comparator (1% clindamycin) in a randomized trial — direct skin benefit from vitamin B3.

PubMed ID: 24029269

Oral nicotinamide reduced pruritus scores in dialysis patients over 4 weeks — direct evidence for improving a skin symptom (itch).

PubMed ID: 26488693

Large randomized phase‑3 trial: oral nicotinamide (vitamin B3) significantly reduced new nonmelanoma skin cancers and actinic keratoses — direct, high-quality evidence for skin benefit.

PubMed ID: 25940759

8‑week split‑face RCT of a topical niacinamide-containing complex showed clear improvements in skin hydration, barrier function and elasticity vs vehicle.

PubMed ID: 30414275

Two randomized trials of a niacinamide-containing cream showed clear improvements in barrier function, hydration and some wrinkle measures.

PubMed ID: 32390309

Topical 3‑ingredient combination including niacinamide was effective for acne vs comparators; niacinamide contribution plausible but not isolated.

PubMed ID: 32478879

Small randomized in vivo study: topical niacinamide partially protected against blue‑light induced skin reddening and pigmentation changes.

PubMed ID: 31461548

Randomized trial of 4% topical niacinamide (n=132) showed increased skin hydration and reduced blemishes vs placebo.

PubMed ID: 22027666

Faster recovery and fewer lasting neurological deficits in pediatric neuroinfections treated with cytoflavin support nervous system health.

PubMed ID: 28300813

Improved neuropsychological outcomes in elderly with alcohol‑related cognitive decline after Cytoflavin — supports nervous system health (indirect).

PubMed ID: 32721104

Oral nicotinamide improved retinal ganglion cell function (PhNR) in glaucoma—robust RCT evidence of benefit to neural tissue.

PubMed ID: 35235774

NR increased brain NAD and reduced inflammatory markers in early Parkinson's, indicating neuroprotective/neuronal metabolic engagement.

PubMed ID: 23250593

Cytoflavin improved neurologic scales and cognitive outcomes after ischemic stroke—direct clinical signal for nervous system benefit (product contains nicotinamide).

PubMed ID: 30668199

EH301 pilot in ALS improved ALSFRS‑R, FVC and strength—supports benefit to motor nervous system though product includes multiple NAD‑related components.

PubMed ID: 20823824

Stroke trial with cytoflavin showed improved neurologic deficit and imaging; supports nervous system benefits though multi‑component.

PubMed ID: 21666588

Neurodevelopmental normalization in preterm infants after multi‑agent treatment including nicotinamide supports nervous system development/health.

PubMed ID: 22329170

Improved coma duration and neurologic outcomes in severe poisoning after cytoflavinum suggest nervous system protection.

PubMed ID: 21350423

Cytoflavin in MS exacerbations reduced EDSS disability and oxidative markers—evidence for nervous system support though cytoflavin is multi‑component.

PubMed ID: 24077550

Cytoflavin produced improvements on neuropsychological tests and P300 in chronic cerebral ischemia — direct nervous system functional measures; multi‑ingredient limits attribution to nicotinamide alone.

PubMed ID: 23994918

Cytoflavin in combined brain injury produced clear neurological improvements (consciousness, neuro signs), supporting nervous system benefit.

PubMed ID: 25589316

Cytoflavin improved distal polyneuropathy severity and antioxidant markers in diabetic foot patients — evidence for peripheral nervous system support.

PubMed ID: 25946854

Stroke study with cytoflavin showed reduced lesion volume and better neurologic/functional outcomes — direct CNS/nervous-system relevance.

PubMed ID: 25591516

Smaller cytoflavin stroke trial with reduced ischemic lesion volume and improved outcomes — supports nervous system benefits (multi‑component).

PubMed ID: 26356615

Large stroke RCT: cytoflavin reduced lesion volume and improved neurologic/functional outcomes — supports nervous system protection/repair (combination product).

PubMed ID: 27017701

Cognitive improvement and increased BDNF with cytoflavin in diabetic patients implies support for nervous system health (moderate evidence; multi‑ingredient).

PubMed ID: 25826870

Cytoflavin (contains nicotinamide) in cerebral infarction improved ischemic volume and neurologic outcomes — supports nervous system benefit in that clinical context (confounded).

PubMed ID: 26601519

Perioperative cytoflavin associated with reduced postoperative cognitive decline and more stable hemodynamics — suggests nervous system protection in surgical patients.

PubMed ID: 28745667

Faster postoperative cognitive recovery with intraoperative Cytoflavin suggests neuroprotective/nervous‑system support.

PubMed ID: 28374695

Cytoflavin in acute ischemic stroke improved neurological deficits and ADLs — strong support for nervous system benefit (multi‑component formulation includes niacinamide).

PubMed ID: 29171485

Reduced postoperative cognitive dysfunction in children given Cytoflavin — supports short‑term nervous system protection (indirect).

PubMed ID: 29359722

Cytoflavin (including nicotinamide) in disseminated encephalomyelitis led to faster recovery and higher rates of complete clinical/MRI regression, indicating nervous-system benefits though product is multi-ingredient.

PubMed ID: 32910863

Adjunct cytoflavin (contains nicotinamide) in hemorrhagic stroke associated with stabilized oxidative markers and lower in‑hospital mortality—suggests CNS benefit in acute injury (nonrandomized).

PubMed ID: 35680173

12-week randomized trial: nicotinamide-containing combination significantly reduced symptoms of diabetic polyneuropathy (paresthesia, numbness) vs placebo.

PubMed ID: 37315248

Cytoflavin (contains nicotinamide plus other agents) improved diabetic neuropathy symptom scores vs placebo (multi‑ingredient limitation).

PubMed ID: 25826870

In patients with cerebral infarction, cytoflavin (contains nicotinamide) reduced ischemic volume and improved neurological status — reasonably strong clinical signal though multi‑ingredient.

PubMed ID: 28300813

Cytoflavin improved cognitive/neuropsychological scores in elderly with alcohol‑related decline — supports brain function (indirect formulation effect).

PubMed ID: 20224285

Donepezil + multivitamin (contains B3) lowered oxidative stress and homocysteine and produced modest MMSE gains vs donepezil+placebo (B3 contribution unclear).

PubMed ID: 25827011

In elderly trauma patients, cytoflavin accelerated regaining consciousness and reduced organ failure — indicates central nervous system benefit (small sample, multi‑component).

PubMed ID: 32721104

Randomized crossover RCT: oral nicotinamide improved inner retinal electrophysiology (PhNR) and showed trend to better visual fields—evidence of neuroprotective effect in ocular neurons.

PubMed ID: 35235774

NR increased cerebral NAD (31P MRS), altered FDG-PET metabolism, lowered inflammation and produced small clinical gains — direct evidence of brain target engagement.

PubMed ID: 9890490

Combination therapy including nicotinic acid improved cerebral blood flow and volunteers reported better memory/well‑being.

PubMed ID: 23250593

Cytoflavin improved neurological and cognitive outcomes after acute ischemic stroke—direct clinical signal for brain support though multi‑ingredient formulation.

PubMed ID: 30668199

Small pilot RCT of EH301 (contains NAD-related compounds) slowed ALS progression and improved respiratory/muscle outcomes—supports nervous system benefit, though composition not pure B3.

PubMed ID: 20823824

Stroke trial with cytoflavin (contains nicotinamide) showed improved brain imaging and neurologic scores; specific attribution to B3 is uncertain but brain benefit evident.

PubMed ID: 21666588

Neurodevelopmental improvements in preterm infants after multi‑agent therapy including nicotinamide suggest brain support.

PubMed ID: 22027666

Faster recovery and fewer residual deficits in pediatric meningitis/encephalitis with cytoflavin indicates a strong brain‑support signal (multi‑component product).

PubMed ID: 22329170

Clinical series in severe opiate poisoning reported shorter coma and lower mortality with cytoflavinum; supports neural protection/recovery.

PubMed ID: 21350423

Cytoflavin in acute MS exacerbations reduced disability scores and oxidative stress—evidence for nervous system/brain support but not niacin‑only.

PubMed ID: 23096033

Small controlled study showed symptomatic and cerebral hemodynamic improvements with cytoflavin added to standard therapy—supports circulation to brain and function.

PubMed ID: 24077550

Objective electrophysiologic (P300) and neuropsychological improvements observed after cytoflavin (includes nicotinamide) in patients with chronic cerebral ischemia — direct brain function measures but multi‑ingredient.

PubMed ID: 23994918

Randomized prospective trial in combined brain injury: cytoflavin (contains nicotinamide) associated with lower illness severity and better neurologic recovery.

PubMed ID: 25518508

Cytoflavin added to standard therapy in hypertensive encephalopathy improved headaches, sleep and QoL, indicating CNS symptomatic benefit.

PubMed ID: 25946854

In stroke patients, cytoflavin reduced ischemic lesion volume (~25–29%) and improved neurologic and functional outcomes.

PubMed ID: 25591516

Randomized stroke trial: cytoflavin reduced ischemic lesion size and improved outcomes — supports brain function benefit though effect may be due to combination therapy.

PubMed ID: 25076759

Severe head‑injury RCT: adding cytoflavin reduced organ failure and improved recovery times — supports brain/system recovery, but confounded by multi‑ingredient therapy.

PubMed ID: 26356615

Large randomized trial in ischemic stroke: cytoflavin reduced lesion volume and improved neurologic/functional status — strong clinical signal for brain protection/repair (combination product).

PubMed ID: 27017701

Cytoflavin improved cognitive test scores and increased BDNF in T2D patients — reasonably direct support for brain function (but multi‑ingredient).

PubMed ID: 26601519

Perioperative cytoflavin use associated with less postoperative cognitive dysfunction — suggests support for short‑term brain function in surgical patients.

PubMed ID: 28745667

Faster cognitive recovery after anesthesia with intraoperative Cytoflavin — supports brain recovery/function.

PubMed ID: 28374695

Dose‑dependent improvement in neurological deficit and ADL in acute ischemic stroke with Cytoflavin (contains niacinamide) — direct brain function benefit (multi‑component).

PubMed ID: 29171485

Reduced short‑term POCD in children given intraoperative Cytoflavin — supports brain function in perioperative setting.

PubMed ID: 41524166

Cognitive (MoCA) gains reported with Cytoflavin (contains nicotinamide) in a randomized example (small, open design).

PubMed ID: 22238957

Cytoflavin lowered oxidative stress markers and improved clinical recovery in severe infection—consistent with support for cellular repair/antioxidant defenses (product includes nicotinamide).

PubMed ID: 25946854

Cytoflavin reduced ischemic lesion volume after stroke (~25–29%) and improved recovery — consistent with enhanced tissue repair/limitation of injury.

PubMed ID: 26356615

Cytoflavin reduced cerebral ischemic lesion volume in a large trial — suggests improved cellular protection/repair in ischemic injury (combination product).

PubMed ID: 20956620

Nicotinamide used as a radiosensitizer in bladder-cancer RT improved survival/relapse outcomes (cellular DNA/repair modulation in oncology context).

PubMed ID: 23719582

ARCON (accelerated radiotherapy + carbogen + nicotinamide) subgroup analysis showed improved regional control and metastasis‑free survival in laryngeal cancer with low CAIX — supports a role for nicotinamide in modifying tumour microenvironment and treatment response.

PubMed ID: 35235774

Brain NAD increases and reduced inflammatory cytokines with NR demonstrate engagement of cellular maintenance pathways in neural tissue.

PubMed ID: 39548320

NR markedly increased whole‑blood NAD+ in RCT, supporting repair pathways dependent on NAD+ (e.g., PARPs, sirtuins).

PubMed ID: 40770531

NR changed urinary NAD metabolites indicating pathway engagement relevant to cellular repair processes (pilot biochemical evidence).

PubMed ID: 41540253

NR/NMN substantially increased systemic NAD+ (cofactor for many repair enzymes, sirtuins, PARPs) — strong mechanistic support.

PubMed ID: 21183910

Cytoflavin (contains nicotinamide) lowered lipid peroxidation and organ‑dysfunction indices in burns, indicating reduced cellular damage (multi-ingredient).

PubMed ID: 21666588

Faster EEG and developmental normalization in preterms treated with a nicotinamide‑containing prep suggests support for cellular/neural maturation and repair.

PubMed ID: 21894767

Burn study with cytoflavin showed increased antioxidant enzyme activity and reduced lipid peroxidation, consistent with cellular protection/repair.

PubMed ID: 22027666

Improved recovery metrics and blood rheology in meningitis/encephalitis with cytoflavin point to enhanced repair and recovery.

PubMed ID: 37245532

Nicotinamide/niacin altered NAD+ and related metabolic pathways central to cellular repair and maintenance mechanisms.

PubMed ID: 31278280

NIAGEN RCT: large, dose-dependent increases in NAD+ and NAD metabolites — NAD is central to many repair/maintenance processes (strong mechanistic evidence).

PubMed ID: 41315336

Topical niacinamide improved melasma/melanin indices and had excellent tolerability — supports epidermal repair and maintenance when applied topically.

PubMed ID: 34518035

Oral nicotinamide reduced Ki67 (cell proliferation marker) in sun‑damaged skin, suggesting effects on cellular turnover/repair pathways.

PubMed ID: 26488693

Nicotinamide reduced actinic keratoses and new skin cancers — consistent with enhanced DNA repair / cellular maintenance mechanisms (direct RCT evidence).

PubMed ID: 24452791

Randomized trial with nicotinamide as part of ARCON improved loco-regional control and DFS in anemic laryngeal cancer patients — mechanistic relevance to cellular response to therapy.

PubMed ID: 23773411

Addition of carbogen + nicotinamide (CON) to radiotherapy markedly improved 5‑year OS in bladder cancers with necrosis — indicates nicotinamide's role in hypoxia modification and tumour response (component of cellular response), though combined therapy.

PubMed ID: 28300813

Elderly with alcohol‑related cognitive decline showed faster/greater cognitive recovery with Cytoflavin (contains niacinamide) — supports mental clarity (multi‑component).

PubMed ID: 41524166

Cytoflavin (contains nicotinamide) infusion improved cognitive test scores/QoL in chronic brucellosis patients.

PubMed ID: 39731767

Cytoflavin (contains nicotinamide) in COVID rehab improved cognition (MMSE) and reduced fatigue; multi-ingredient but cognitive signal present.

PubMed ID: 29171485

In children, intraoperative Cytoflavin reduced postoperative cognitive dysfunction vs control — supports acute mental clarity recovery (indirect).

PubMed ID: 28374695

Cytoflavin added to stroke care improved neuropsychological/functional recovery (dose‑dependent) — supports clearer cognition post‑injury.

PubMed ID: 28745667

Intraoperative Cytoflavin associated with faster early cognitive recovery after anesthesia — improved short‑term clarity (indirect).

PubMed ID: 25826870

Cytoflavin (multi‑ingredient including nicotinamide) in cerebral infarction improved neurological outcomes and reduced ischemic volume — supports improved brain/mental function post‑event (confounded).

PubMed ID: 27017701

Small RCT in T2D patients: cytoflavin (contains nicotinamide) improved MoCA cognitive scores and raised BDNF — supports cognitive/clarity effects though multi‑ingredient.

PubMed ID: 26356615

Large cytoflavin stroke trial showed improved clinical/cognitive outcomes vs control — multi‑component but suggests improved cognitive/clarity measures.

PubMed ID: 25591516

Smaller randomized stroke trial: cytoflavin reduced lesion volume and associated clinical improvements (multi‑ingredient; supports mental clarity indirectly).

PubMed ID: 25946854

Cytoflavin after stroke reduced lesion size and improved neurologic/functional outcomes, consistent with improved cognitive/clarity endpoints.

PubMed ID: 23994918

Cytoflavin (includes nicotinamide) in brain‑injury patients associated with faster recovery of consciousness and improved neurological signs.

PubMed ID: 22027666

Children with meningitis/encephalitis treated with cytoflavin recovered faster and had fewer lasting problems; relevant to cognitive recovery.

PubMed ID: 20823824

Stroke patients given cytoflavin (includes nicotinamide) showed better neurologic scores and brain imaging vs control; effect cannot be attributed solely to B3 but supports cognitive/clarity benefit.

PubMed ID: 23250593

Cytoflavin (contains nicotinamide) produced greater cognitive and neurologic recovery vs comparator in acute ischemic stroke—suggests benefit to cognition/clarity though multi‑component drug confounds attribution.

PubMed ID: 35235774

Small clinical gains in early Parkinson's patients were tied to increased brain NAD and metabolic changes, implying possible cognitive/clarity benefits in responders.

PubMed ID: 19874992

Niacin reduced carotid plaque area over 12 months—plausible benefit for vascular aging.

PubMed ID: 19735523

Niacinamide-containing products produced measurable short-term improvements in wrinkle metrics.

PubMed ID: 28468736

Nicotinamide reduced actinic keratoses and prevented new lesions in high‑risk (transplant) patients — implication for skin‑related aging/cancer prevention.

PubMed ID: 24618208

ER‑niacin reduced oxidative stress biomarkers (ox‑LDL, urine/plasma F2‑isoprostanes) which may relate to healthy aging mechanisms.

PubMed ID: 37245532

Placebo‑controlled metabolomics study showed nicotinamide/niacin produced acute NAD+‑related metabolic effects linked to aging biology.

PubMed ID: 41312593

Topical niacinamide-containing formulation improved multiple skin-aging endpoints (wrinkles, firmness, radiance).

PubMed ID: 31278280

NIAGEN (nicotinamide riboside) RCT: dose-dependent large increases in NAD+ — plausible mechanism for aging-related cellular support (biomarker-level evidence).

PubMed ID: 35235774

Nicotinamide riboside in early Parkinson's increased brain NAD, changed brain metabolism and lowered inflammation — biologic signs consistent with potential anti‑aging/neuroprotective effects.

PubMed ID: 39548320

Nicotinamide riboside (NR) raised whole‑blood NAD+ substantially in 6‑week RCT, a mechanism often invoked for healthy aging.

PubMed ID: 41540253

NR/NMN doubled whole‑blood NAD+ — plausible mechanism for supporting hallmarks of aging (mechanistic evidence).

PubMed ID: 10856529

Colestipol‑plus‑niacin reduced atherosclerosis progression (IMT/angiography) in men with CAD—plausibly slows vascular aging.

PubMed ID: 20399059

Niacin induced regression of carotid atherosclerosis (CIMT) — surrogate of vascular aging; suggests possible contribution to healthy vascular aging though clinical outcome data are limited.

PubMed ID: 34958693

Topical niacinamide (with 4‑HR) improved visible signs of skin ageing (wrinkles, elasticity) in an RCT.

PubMed ID: 30414275

Niacinamide cream produced modest wrinkle/texture improvements consistent with anti‑aging cosmetic effects.

PubMed ID: 19017042

Reduction in periorbital wrinkles/roughness suggests an anti‑aging cosmetic effect.

PubMed ID: 18047609

Anti-wrinkle and hydration effects of topical niacinamide support improvements in skin aging signs.

PubMed ID: 16029679

Topical niacinamide reduced fine lines/wrinkles and improved firmness — relevant to appearance-related aging.

PubMed ID: 20374604

Multicomponent regimen including niacinamide reduced wrinkle area fraction vs tretinoin with less irritation (appearance/aging outcome).

PubMed ID: 16461040

Coronary Drug Project: long‑term niacin after MI lowered recurrent MI and reduced 15‑year mortality—supports aging-related outcomes.

PubMed ID: 20061726

Improved pigmentation and texture from niacinamide lotion can contribute to healthier/younger-looking skin.

PubMed ID: 12637338

Increases in protective HDL subfractions associated with less arterial progression over 3 years—supports vascular aspects of healthy aging.

PubMed ID: 28165180

Niacinamide in faster‑acting insulin formulation produced earlier insulin appearance and reduced early postprandial glucose excursion — directly relevant to post‑meal glucose→energy metabolism.

PubMed ID: 10356941

Multivitamin (raised B3) increased appetite, weight and muscular strength in recovering children — consistent with reduced fatigue and improved vigor (multi‑nutrient).

PubMed ID: 39731767

Cytoflavin given in post-COVID rehab reduced fatigue measures and increased exercise tolerance (multi-ingredient but clinical benefit observed).

PubMed ID: 25518508

Cytoflavin reduced asthenia/autonomic disorder scores and improved sleep in hypertensive encephalopathy — direct symptomatic improvement in fatigue-related measures.

PubMed ID: 22238957

Cytoflavin contains metabolic substrates including nicotinamide (NAD precursor) and was associated with faster recovery and reduced oxidative stress in ICU patients—consistent with improved cellular energy handling though multi‑ingredient limits attribution.

PubMed ID: 41540253

NR and NMN roughly doubled whole‑blood NAD+ after 14 days — strong mechanistic evidence for enhanced cellular energy cofactor availability.

PubMed ID: 40770531

NR altered urinary NAD catabolites showing uptake into NAD metabolism — biochemical support for energy pathway engagement.

PubMed ID: 39548320

NR raised whole‑blood NAD+ substantially in an RCT, indicating enhanced NAD+ availability for energy metabolism.

PubMed ID: 35235774

NR raised cerebral NAD levels (brain energy cofactor), indicating increased energy-related metabolites in neural tissue.

PubMed ID: 31278280

NIAGEN RCT: dose-dependent large increases in blood NAD+ and NAD-related metabolites — direct mechanistic evidence for enhanced cellular energy capacity.

PubMed ID: 37245532

Direct evidence of NAD+‑related metabolic pathway activation after nicotinamide/niacin exposure—core to cellular energy production.

PubMed ID: 40355744

Large RCT: oral nicotinamide early in COVID accelerated recovery of physical performance and reduced fatigue-related outcomes versus placebo.

PubMed ID: 25827011

Cytoflavin (metabolic cocktail including nicotinamide) produced clinical recovery benefits in trauma patients consistent with improved cellular energy metabolism (combination product evidence).

PubMed ID: 23657156

Niacin‑related metabolites (nicotinuric acid, trigonelline) and acylcarnitine changes after dietary intervention indicate modulation of NAD/NADP‑linked metabolic pathways—relevant to cellular energy cycling (indirect dietary evidence).

PubMed ID: 28556616

Niacinamide in the faster-aspart insulin formulation markedly accelerated insulin appearance and ~2× greater early insulin exposure and glucose-lowering vs standard aspart — direct evidence for improved early post-prandial glycemic control attributable to the niacinamide-containing formulation (excipient effect).

PubMed ID: 28165180

Niacinamide in an insulin formulation accelerated insulin absorption and improved early postprandial glucose control — directly relevant to glycemic balance (excipient effect).

PubMed ID: 7956639

Adding short‑term deflazacort to nicotinamide slightly increased stimulated insulin secretion after 1 year compared with nicotinamide alone — modest effect on beta‑cell function (adjunct therapy).

PubMed ID: 8961125

Large school‑based prevention program: testing/treatment strategy including nicotinamide associated with substantially lower incidence of insulin‑dependent diabetes over ~7 years — strong population signal for diabetes prevention.

PubMed ID: 7556988

One‑year RCT: no overall change in insulin needs/HbA1c, but older adolescents/adults (>15 y) showed improved stimulated C‑peptide — subgroup evidence of preserved beta‑cell function.

PubMed ID: 8181261

Randomized multicenter trial: nicotinamide modestly increased short‑term insulin‑independence (clinical remission) in recent‑onset type‑1 diabetes — direct glycemic/insulin requirement benefit.

PubMed ID: 28468736

Nicotinamide supplementation in transplant recipients prevented new actinic keratoses and reduced progression to SCC — implies immune/anticarcinogenic benefit in immunosuppressed patients.

PubMed ID: 16950175

Niacin reduced inflammatory markers (CRP, Lp‑PLA2) in coronary patients—supporting anti‑inflammatory/immune modulation.

PubMed ID: 22709272

Topical and oral nicotinamide markedly reduced PDT‑induced suppression of delayed‑type hypersensitivity in humans—strong, direct evidence for immunomodulatory/protective effects.

PubMed ID: 40810569

Nicotinamide was part of interventions associated with anecdotal prolonged HIV control in a very small trial — suggestive immunomodulatory signal but underpowered and confounded.

PubMed ID: 27187447

Oral supplement (contains 10 mg niacin) produced blood gene‑expression changes linked to interferon signaling/antiviral pathways — suggests potential immune‑modulating effects (multi‑ingredient).

PubMed ID: 39548320

NR significantly lowered sputum IL‑8 (airway inflammation) in older ex‑smokers with COPD, indicating anti‑inflammatory immune effects.

PubMed ID: 36082508

NRPT (nicotinamide riboside + pterostilbene) trial in NAFLD showed modest, significant reductions in ALT and GGT (reduced hepatic inflammation) despite no change in liver fat.

PubMed ID: 36286675

IV formulation containing nicotinamide (Remaxol) produced non-inferior improvements in liver biochemistry in cholestasis — effect cannot be ascribed solely to nicotinamide but is directly relevant to liver tests.

PubMed ID: 26420678

Randomized pediatric hemodialysis trial: nicotinamide added to phosphate binders significantly lowered serum phosphorus and Ca×P product—consistent with reduced intestinal phosphate absorption via nicotinamide (mechanistically digestive tract related).

PubMed ID: 26073389

Pooled safety data report increased GI adverse events (nausea/diarrhea) with ER niacin; directly relevant to digestive tolerability.

PubMed ID: 16461040

Long-term niacin therapy after MI reduced recurrent MI and 15‑year mortality—plausibly linked to improved long-term vitality/health span.

PubMed ID: 26978497

Study reported that a cytoprotective product containing nicotinamide improved clinical outcomes and stress‑resistance measures over 1 year (qualitative reporting; multi‑ingredient).

PubMed ID: 38281653

In dialysis patients, niacin lowered serum phosphorus by ~0.7–1.0 mg/dL—clinically relevant removal of a retained solute in that population (detox-like effect).

PubMed ID: 8841834

Double‑blind placebo RCT in osteoarthritis: oral niacinamide improved global arthritis impact, reduced ESR and increased joint mobility — direct evidence for joint comfort.

PubMed ID: 10356941

Multivitamin including B3 increased appetite and calorie intake in children recovering from illness (direct clinical finding).

PubMed ID: 16887123

ER niacin markedly raised leptin (+26.8%) in 6‑week trial—biologically plausible effect on appetite regulation.